News Akeso, Inc. BOERSE MUENCHEN

Equities

4RY

KYG0146B1032

Real-time BOERSE MUENCHEN Other stock markets 12:13:47 04/07/2024 am IST			5-day change	1st Jan Change
4.46 ^EUR	+0.45%		-2.20%	-16.23%

01/07	Akeso, Inc. Announces Change of Directors	CI
04/06	Akeso Expands Territory of License Agreement for Lung Cancer Drug	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Akeso, Inc. Announces Change of Directors	01/07	CI
Akeso Expands Territory of License Agreement for Lung Cancer Drug	04/06	MT
Summit Therapeutics Inc. Expands License Territories for Ivonescimab	03/06	CI
Akeso's Phase 3 Trial for Non-Small Cell Lung Cancer Treatment Meets Primary Endpoint; Shares Rise 15%	31/05	MT
Akeso, Inc. Announces Registration Phase III Clinical Trial, AK112-303 (HARMONi-2) of ivonescimab (AK112, PD-1/VEGF)	31/05	CI
Akeso, Inc. Announces Phase III Clinical Trial, Harmoni-2 or AK112-303 Met Its Primary Endpoint of Progression-Free Survival	30/05	CI
Hong Kong Shares End Week in Red; Sunho Biologics Gains in Debut	24/05	MT
Akeso Lung Cancer Drug Gets NMPA's Marketing Approval; Stocks Crash 20%	24/05	MT
Akeso, Inc. Receives NMPA's Marketing Approval in China for Ivonescimab Injection	24/05	CI
Akeso’s Supplemental New Drug Application for Cervical Cancer Drug Accepted by Chinese Regulator	24/04	MT
National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer	24/04	CI
Summit Therapeutics Inc. - Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024	25/03	AQ
Akeso to Raise Over HK$1 Billion Via Share Sale	22/03	MT
Akeso Logs First-Ever Profit in 2023; Beats EPS Forecast	19/03	MT
Akeso, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03	CI
Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC	06/03	CI
Akeso Books First-Ever Profit in 2023; Shares Fall 5%	05/03	MT
Akeso, Inc. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023	05/03	CI
Nomura Adjusts Akeso’s Price Target to HK$52.80 From HK$48.84, Keeps at Buy	23/02	MT
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials	16/02	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Akeso, Inc. BOERSE MUENCHEN

Equities

4RY

KYG0146B1032

Summary

Filters